Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 17/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 17/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13345003 | 0.79 | HPGD (0.43) | MEN1KMT2A | |
| SCHEMBL3559992 | 0.72 | ADH1A (0.37) | LCK | |
| SCHEMBL13131610 | 0.70 | MTNR1A (0.48) | MTNR1AMTNR1B | |
| SCHEMBL2259224 | 0.68 | ALDH1A1 (0.44) | MTNR1A | |
| SCHEMBL10064018 | 0.68 | LCK (0.41) | LCKMEN1KMT2A | |
| SCHEMBL10030448 | 0.68 | LCK (0.41) | LCKMEN1KMT2A | |
| SCHEMBL12365494 | 0.67 | ALDH1A1 (0.43) | MTNR1AMTNR1B | |
| SCHEMBL785024 | 0.66 | CA12 (0.45) | MTNR1AMEN1KMT2A | |
| SCHEMBL16502580 | 0.66 | PDK2 (0.47) | MTNR1AMTNR1BLCKMEN1KMT2A | |
| SCHEMBL9644030 | 0.66 | CA1 (0.55) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | HTR2C 1207/4885MTNR1A 253/4885MTNR1B 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.